De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways (Haematologica, 2019)

(untitled) - Magistroni, V; Mauri, M; D'Aliberti, D; Mezzatesta, C; Crespiatico, I; Nava, M; Fontana, D; Sharma, N; Parker, W; Schreiber, A; Yeung, D; Pirola, A; et al.